Korea FilingsFull brief — $39

YUNGJIN PHARM. CO., LTD

영진약품(주) · KOSPI: 003520 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
영진약품(주)
Market / ticker
KOSPI · 003520
Industry
Pharmaceuticals and medicinal chemicals
Established
1962-07-16
Fiscal year ends
December
Website
www.yungjin.co.kr
DART corp code
00141149
Latest revenue
₩254.3B (FY2025)

Items worth checking

medium
Litigation filed or ruled — filed on 2 separate dates in the last 12 months, latest 2026-09-01.
medium
Decision to issue convertible / warrant / exchangeable bonds — the filing states whether new or treasury shares back it — filed 2025-11-20.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩234.9B₩252.0B₩254.3B
Operating income₩3.1B₩8.7B₩3.4B
Net income−₩3.9B₩1.2B−₩228M
Total assets₩226.6B₩234.3B₩262.4B
Total liabilities₩137.0B₩144.5B₩170.9B
Total equity₩89.6B₩89.8B₩91.5B
Share capital₩91.4B₩91.4B₩91.4B

Separate statements · FY2025 operating margin 1.3% · liabilities to equity 187% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 64 (current)한울회계법인Unqualified
Term 63 (prior)한영회계법인Unqualified
Term 62 (two years prior)한영회계법인Unqualified

Largest shareholder history

No change history reported in the latest annual report.

Recent filings

DateFilingOriginal
2026-09-01Litigation filedDART
2026-08-28Large business group status disclosureDART
2026-08-14Half-year report (2026.06)DART
2026-08-13Payment terms to suppliers and dispute mediation bodyDART
2026-08-12Amended: Single sales / supply contract signedDART
2026-07-31Preliminary operating results (fair disclosure)DART
2026-07-24Amended: New facility investmentDART
2026-06-01Large business group status disclosureDART
2026-05-28Corporate governance reportDART
2026-05-15Quarterly report (2026.03)DART
2026-05-06Preliminary operating results (fair disclosure)DART
2026-03-20Independent director appointment / dismissal / resignationDART
2026-03-20Annual general meeting resultsDART
2026-03-12Annual report (2025.12)DART
2026-03-12Amended: Proxy solicitation reference documentDART
2026-03-12Amended: Notice of shareholders meetingDART
2026-03-05Proxy solicitation reference documentDART
2026-03-05Notice of shareholders meetingDART
2026-03-03Audit report submittedDART
2026-02-27Resolution to convene shareholders meetingDART

Showing the 20 most recent of 33 filings. The full brief lists all of them.

Full brief on YUNGJIN PHARM. CO., LTD — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.